Kronos Bio Inc - Company Profile
Powered by 
All the sales intelligence you need on Kronos Bio Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Kronos Bio Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Kronos Bio Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Kronos Bio Inc (Kronos Bio) is a clinical-stage biopharmaceutical company that discovers and develops therapeutics for cancer and other autoimmune diseases. The company pipeline products include KB-9558, which targets relapsed, refractory multiple myeloma and human papillomavirus-driven tumors; KB-7898 is an autoimmune development candidate, which inhibits the lysine acetyltransferase (KAT) domain of p300 for the treatment of Sjogren’s disease. Kronos Bio other pipeline include KB-0742 for the indication of ovarian cancer. It operates through its research facility and offices in Cambridge and Massachusetts, the US. Kronos Bio is headquartered in San Mateo, California, the US.
Headquarters
United States of America
Address
Suite 400, 1300 South El Camino Real, San Mateo, California, 94402
No of Employees
8
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$9.8M
Kronos Bio Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| KB-9558: Relapsed/ Refractory Multiple Myeloma, Human Papillomavirus-Driven Tumors |
| KB-7898: Sjogren’s Disease |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Asset Disposal | In October, the company sold its Clinical Pipeline to Ignota Labs, a pharmaceutical company. |
| 2025 | Contracts/Agreements | In May, the company signed an agreement to be acquired by Concentra Biosciences, LLC. |
| 2023 | Contracts/Agreements | In January, the company entered into a discovery collaboration in the field of oncology with Genentech to focus on discovery and development of small-molecule drugs. |
Competitor Comparison
| Key Parameters | Kronos Bio Inc | Arrowhead Pharmaceuticals Inc | PTC Therapeutics Inc | Axsome Therapeutics Inc | Alector Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Mateo | Pasadena | Warren | New York City | South San Francisco |
| State/Province | California | California | New Jersey | New York | California |
| No. of Employees | 8 | 711 | 939 | 683 | 156 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Arie S. Belldegrun, M.D | Chairman | Executive Board | 2017 | 75 |
| Deborah Knobelman, Ph.D. | Chief Operating Officer; Interim Chief Executive Officer; President; Chief Financial Officer | Senior Management | 2024 | - |
| Joshua Kazam? | Director | Non Executive Board | 2017 | 48 |
| David M. Tanen | Director | Non Executive Board | 2017 | 53 |
| Elena Ridloff | Director | Non Executive Board | 2020 | 45 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer